
Claims:

1. A method for treating or preventing multiple sclerosis, comprising orally administering to a patient in need thereof a compound of Formula I at a daily amount ranging from about 20 mg to about 300 mg or a pharmaceutically acceptable salt thereof, wherein Formula I is represented by:



2. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount ranging from about 20 mg to about 200 mg or a pharmaceutically acceptable salt thereof.
3. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount ranging from about 30 mg to about 300 mg or a pharmaceutically acceptable salt thereof.
4. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount ranging from about 25 mg to about 150 mg or a pharmaceutically acceptable salt thereof.
5. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount ranging from about 85 mg to about 95 mg or a pharmaceutically acceptable salt thereof.
6. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount ranging from about 25 mg to about 50 mg or a pharmaceutically acceptable salt thereof.
7. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount ranging from about 50 mg to about 75 mg or a pharmaceutically acceptable salt thereof.

8. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount ranging from about 75 mg to about 100 mg or a pharmaceutically acceptable salt thereof.

9. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount ranging from about 100 mg to about 125 mg or a pharmaceutically acceptable salt thereof.

10. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount ranging from about 125 mg to about 150 mg or a pharmaceutically acceptable salt thereof.

11. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount of about 90 mg or a pharmaceutically acceptable salt thereof.

12. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount of 90 mg or a pharmaceutically acceptable salt thereof.

13. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount of about 90 mg.

14. The method of claim 1, wherein the patient is orally administered a compound of Formula I at a daily amount of 90 mg.

15. The method of any one of claims 1-14, wherein the compound of Formula I or a pharmaceutically acceptable salt thereof is administered only once per day.

16. The method of any one of claims 1-14, wherein the compound of Formula I or a pharmaceutically acceptable salt thereof is administered twice per day.

17. The method of claim 1, wherein the patient is orally administered twice per day a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of about 45 mg or a pharmaceutically acceptable salt thereof.

18. The method of claim 1, wherein the patient is orally administered twice per day a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of 45 mg or a pharmaceutically acceptable salt thereof.

19. The method of claim 1, wherein the patient is orally administered twice per day a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of about 45 mg.

20. The method of claim 1, wherein the patient is orally administered twice per day a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of 45 mg.

21. The method of any one of claims 1-20, wherein the patient has recently consumed food prior to receiving said compound.

22. The method of any one of claims 1-20, wherein the patient has consumed food within 1 hour prior to receiving said compound.


23. The method of any one of claims 1-20, wherein the patient has not recently consumed food prior to receiving said compound.

24. The method of any one of claims 1-20, wherein the patient has not consumed food within 1 hour prior to receiving said compound.

25. The method of any one of claims 1-20, wherein the patient consumes a meal within 1 hour of receiving said compound.

26. The method of any one of claims 1-20, wherein the administering is performed at a time the patient consumes a meal.

27. A method for treating or preventing multiple sclerosis, comprising orally administering to a patient in need thereof a once daily dosage of a compound of Formula I in an amount ranging from about 50 mg to about 100 mg or a pharmaceutically acceptable salt thereof, wherein Formula I is represented by:



28. The method of claim 27, wherein the once daily dosage is administered to the patient in the form of a single unit formulation containing compound of Formula I or a pharmaceutically acceptable salt thereof.

29. The method of claim 27, wherein the once daily dosage is administered to the patient in the form of two or more unit formulations containing compound of Formula I or a pharmaceutically acceptable salt thereof.

30. The method of claim 27, wherein the once daily dosage is administered to the patient in the form of three unit formulations containing compound of Formula I or a pharmaceutically acceptable salt thereof.

31. The method of claim 27, wherein the once daily dosage is administered to the patient in the form of three unit formulations each containing compound of Formula I in an amount of about 25 mg.

32. The method of any one of claims 28-31, wherein the unit formulation(s) are a tablet or capsule.

33. The method of any one of claims 27-32, wherein the once daily dosage is about 75 mg of the compound of Formula I.

34. The method of any one of claims 27-32, wherein the once daily dosage is 75 mg of the compound of Formula I.

35. The method of any one of claims 27-34, wherein the once daily dosage is administered to the patient in the morning.

36. The method of any one of claims 27-35, wherein the patient has consumed food within 2 hours prior to receiving the once daily dosage.

37. The method of any one of claims 27-35, wherein the patient has consumed food within 1 hour prior to receiving the once daily dosage.

38. The method of any one of claims 27-35, wherein the patient consumes food within 30 minutes of receiving the once daily dosage.


39. The method of any one of claims 27-38, wherein the patient receives the once daily dosage for a duration of at least 2 weeks.

40. The method of any one of claims 27-38, wherein the patient receives the once daily dosage for a duration of at least 1 month.

41. The method of any one of claims 27-38, wherein the patient receives the once daily dosage for a duration of at least 6 months.

42. A method for treating or preventing multiple sclerosis, comprising orally administering to a patient in need thereof two times per day a unit dosage containing a compound of Formula I

in an amount ranging from about 25 mg to about 50 mg or a pharmaceutically acceptable salt thereof, wherein Formula I is represented by:



43. The method of claim 42, wherein the unit dosage is administered to the patient in the form of two or more unit formulations containing compound of Formula I or a pharmaceutically acceptable salt thereof.

44. The method of claim 42, wherein the unit dosage is administered to the patient in the form of two unit formulations containing compound of Formula I or a pharmaceutically acceptable salt thereof.

45. The method of claim 42, wherein the unit dosage is administered to the patient in the form of a single unit formulation containing compound of Formula I or a pharmaceutically acceptable salt thereof.

46. The method of any one of claims 43-45, wherein the unit formulation(s) are a tablet or capsule.

47. The method of any one of claims 42-46, wherein the unit dosage contains the compound of Formula I in the amount of about 35 mg.

48. The method of any one of claims 42-46, wherein the unit dosage contains the compound of Formula I in the amount of 35 mg.

49. The method of any one of claims 42-48, wherein there is at least 8 hours between administration of a first unit dosage and a second unit dosage to the patient on the same day.


50. The method of any one of claims 42-49, wherein a first unit dosage is administered to the patient in the morning, and a second unit dosage is administered to the patient in the evening.

51. The method of any one of claims 42-50, wherein the patient has consumed food within 2 hours prior to receiving the unit dosage.

52. The method of any one of claims 42-50, wherein the patient has consumed food within 1 hour prior to receiving the unit dosage.

53. The method of any one of claims 42-50, wherein the patient consumes food within 30 minutes of receiving the unit dosage.

54. A method for treating or preventing multiple sclerosis, comprising orally administering to a patient in need thereof twice daily a unit dosage containing a compound of Formula I in an amount of about 45 mg or a pharmaceutically acceptable salt thereof, wherein the patient consumes a meal within about 1 hour of said administering, and Formula I is represented by:



55. The method of claim 54, wherein the unit dosage is administered to the patient in the form of one or more unit formulations containing compound of Formula I or a pharmaceutically acceptable salt thereof.

56. The method of claim 55, wherein the unit formulation(s) are a tablet or capsule.

57. The method of any one of claims 54-56, wherein the unit dosage contains about 45 mg of compound of Formula I.

58. The method of any one of claims 54-56, wherein the unit dosage contains 45 mg of compound of Formula I.

59. The method of any one of claims 54-58, wherein said administering is performed at the time the patient consumes a meal.

60. The method of any one of claims 54-59, wherein there is at least 8 hours between administration of a first unit dosage and a second unit dosage to the patient on the same day.

61. The method of any one of claims 54-60, wherein a first unit dosage is administered to the patient in the morning, and a second unit dosage is administered to the patient in the evening.

62. The method of any one of claims 54-58, wherein a first unit dosage is administered to the patient at the time the patient consumes a breakfast meal in the morning, and a second unit dosage is administered to the patient at the time the patient consumes a dinner meal in the evening.

63. The method of any one of claims 42-62, wherein the patient receives the unit dosage two times per day for a duration of at least 2 weeks.

64. The method of any one of claims 42-62, wherein the patient receives the unit dosage two times per day for a duration of at least 1 month.

65. The method of any one of claims 42-62, wherein the patient receives the unit dosage two times per day for a duration of at least 6 months.

66. The method of any one of claims 1-65, wherein the method is for treating multiple sclerosis.

67. The method of any one of claims 1-65, wherein the method is for preventing multiple sclerosis.

68. The method of any one of claims 1-67, wherein the multiple sclerosis is relapsing multiple sclerosis, relapsing-remitting multiple sclerosis, progressive multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, or progressive-relapsing multiple sclerosis.

69. The method of any one of claims 1-67, wherein the multiple sclerosis is relapsing multiple sclerosis.

70. The method of any one of claims 1-69, wherein the patient is an adult human.

71. The method of any one of claims 1-70, wherein the patient experiences at least a 5% reduction in the number of gadolinium positive T1 magnetic resonance imaging lesions after receiving for a duration of 24 weeks the compound of Formula I or a pharmaceutically acceptable salt thereof.

72. The method of any one of claims 1-70, wherein the patient experiences at least a 15% reduction in the number of gadolinium positive T1 magnetic resonance imaging lesions after receiving for a duration of 24 weeks the compound of Formula I or a pharmaceutically acceptable salt thereof.

73. The method of any one of claims 1-70, wherein the patient experiences at least a 30% reduction in the number of gadolinium positive T1 magnetic resonance imaging lesions

after receiving for a duration of 24 weeks the compound of Formula I or a pharmaceutically acceptable salt thereof.

74. The method of any one of claims 1-70, wherein the patient experiences at least a 50% reduction in the number of gadolinium positive T1 magnetic resonance imaging lesions after receiving for a duration of 24 weeks the compound of Formula I or a pharmaceutically acceptable salt thereof.

75. The method of any one of claims 1-74, wherein the patient experiences at least a 5% reduction in the collective size of gadolinium positive T1 magnetic resonance imaging lesions after receiving for a duration of 24 weeks the compound of Formula I or a pharmaceutically acceptable salt thereof.

76. The method of any one of claims 1-74, wherein the patient experiences at least a 15% reduction in the collective size of gadolinium positive T1 magnetic resonance imaging lesions after receiving for a duration of 24 weeks the compound of Formula I or a pharmaceutically acceptable salt thereof.

77. The method of any one of claims 1-74, wherein the patient experiences at least a 30% reduction in the collective size of gadolinium positive T1 magnetic resonance imaging lesions after receiving for a duration of 24 weeks the compound of Formula I or a pharmaceutically acceptable salt thereof.

78. The method of any one of claims 1-74, wherein the patient experiences at least a 50% reduction in the collective size of gadolinium positive T1 magnetic resonance imaging lesions after receiving for a duration of 24 weeks the compound of Formula I or a pharmaceutically acceptable salt thereof.